Reuters logo
BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06
November 7, 2017 / 9:32 PM / 10 days ago

BRIEF-Alnylam Pharmaceuticals Q3 non-gaap loss per share $1.06

Nov 7 (Reuters) - Alnylam Pharmaceuticals Inc:

* Alnylam Pharmaceuticals reports third quarter 2017 financial results and highlights recent period activity

* Q3 non-gaap loss per share $1.06

* Q3 earnings per share view $-1.26 -- Thomson Reuters I/B/E/S

* Alnylam Pharmaceuticals-qtrly ‍cash,cash equivalents,fixed income marketable securities,restricted investments $1.15 billion versus $1.09 billion at Dec 31,2016​

* Alnylam Pharmaceuticals Inc - ‍remains on track to end 2017 with greater than $1.0 billion in cash, cash equivalents and fixed income marketable securities​

* Alnylam Pharmaceuticals Inc says qtrly net loss per common share - basic and diluted $1.34‍​

* Alnylam Pharmaceuticals Inc - qtrly net revenues from collaborators $17.1 million versus $13.7 million ‍​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below